The Cooper Companies, Inc.
The Cooper Companies, Inc. COO Peers
See (COO) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Instruments & Supplies Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| COO | $84.44 | +2.64% | 16.89B | 40.79 | $2.07 | N/A |
| ISRG | $561.43 | +4.64% | 201.23B | 82.44 | $6.81 | N/A |
| BDX | $175.32 | +4.84% | 50.25B | 33.98 | $5.16 | +2.28% |
| BDXA | $59.24 | -2.24% | 47.95B | 21.44 | $2.76 | +2.28% |
| ALC | $94.80 | -0.99% | 46.89B | 46.24 | $2.05 | +0.28% |
| RMD | $247.69 | +1.08% | 36.32B | 27.80 | $8.91 | +0.86% |
| BAX | $31.89 | +3.19% | 16.36B | -61.32 | -$0.52 | +2.90% |
| WST | $219.35 | +2.95% | 15.76B | 34.43 | $6.37 | +0.38% |
| BDXB | $48.16 | +1.39% | 13.69B | 7.60 | $6.33 | +2.28% |
| HOLX | $58.81 | +3.63% | 13.11B | 24.71 | $2.38 | N/A |
Stock Comparison
COO vs ISRG Comparison
COO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COO stands at 16.89B. In comparison, ISRG has a market cap of 201.23B. Regarding current trading prices, COO is priced at $84.44, while ISRG trades at $561.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COO currently has a P/E ratio of 40.79, whereas ISRG's P/E ratio is 82.44. In terms of profitability, COO's ROE is +0.05%, compared to ISRG's ROE of +0.16%. Regarding short-term risk, COO and ISRG have similar daily volatility (1.83).
COO vs BDX Comparison
COO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COO stands at 16.89B. In comparison, BDX has a market cap of 50.25B. Regarding current trading prices, COO is priced at $84.44, while BDX trades at $175.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COO currently has a P/E ratio of 40.79, whereas BDX's P/E ratio is 33.98. In terms of profitability, COO's ROE is +0.05%, compared to BDX's ROE of +0.06%. Regarding short-term risk, COO is less volatile compared to BDX. This indicates potentially lower risk in terms of short-term price fluctuations for COO.
COO vs BDXA Comparison
COO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COO stands at 16.89B. In comparison, BDXA has a market cap of 47.95B. Regarding current trading prices, COO is priced at $84.44, while BDXA trades at $59.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COO currently has a P/E ratio of 40.79, whereas BDXA's P/E ratio is 21.44. In terms of profitability, COO's ROE is +0.05%, compared to BDXA's ROE of +0.06%. Regarding short-term risk, COO is less volatile compared to BDXA. This indicates potentially lower risk in terms of short-term price fluctuations for COO.
COO vs ALC Comparison
COO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COO stands at 16.89B. In comparison, ALC has a market cap of 46.89B. Regarding current trading prices, COO is priced at $84.44, while ALC trades at $94.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COO currently has a P/E ratio of 40.79, whereas ALC's P/E ratio is 46.24. In terms of profitability, COO's ROE is +0.05%, compared to ALC's ROE of +0.06%. Regarding short-term risk, COO is more volatile compared to ALC. This indicates potentially higher risk in terms of short-term price fluctuations for COO.
COO vs RMD Comparison
COO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COO stands at 16.89B. In comparison, RMD has a market cap of 36.32B. Regarding current trading prices, COO is priced at $84.44, while RMD trades at $247.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COO currently has a P/E ratio of 40.79, whereas RMD's P/E ratio is 27.80. In terms of profitability, COO's ROE is +0.05%, compared to RMD's ROE of +0.25%. Regarding short-term risk, COO is more volatile compared to RMD. This indicates potentially higher risk in terms of short-term price fluctuations for COO.
COO vs BAX Comparison
COO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COO stands at 16.89B. In comparison, BAX has a market cap of 16.36B. Regarding current trading prices, COO is priced at $84.44, while BAX trades at $31.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COO currently has a P/E ratio of 40.79, whereas BAX's P/E ratio is -61.32. In terms of profitability, COO's ROE is +0.05%, compared to BAX's ROE of -0.05%. Regarding short-term risk, COO is less volatile compared to BAX. This indicates potentially lower risk in terms of short-term price fluctuations for COO.
COO vs WST Comparison
COO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COO stands at 16.89B. In comparison, WST has a market cap of 15.76B. Regarding current trading prices, COO is priced at $84.44, while WST trades at $219.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COO currently has a P/E ratio of 40.79, whereas WST's P/E ratio is 34.43. In terms of profitability, COO's ROE is +0.05%, compared to WST's ROE of +0.17%. Regarding short-term risk, COO is less volatile compared to WST. This indicates potentially lower risk in terms of short-term price fluctuations for COO.
COO vs BDXB Comparison
COO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COO stands at 16.89B. In comparison, BDXB has a market cap of 13.69B. Regarding current trading prices, COO is priced at $84.44, while BDXB trades at $48.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COO currently has a P/E ratio of 40.79, whereas BDXB's P/E ratio is 7.60. In terms of profitability, COO's ROE is +0.05%, compared to BDXB's ROE of +0.06%. Regarding short-term risk, COO is less volatile compared to BDXB. This indicates potentially lower risk in terms of short-term price fluctuations for COO.
COO vs HOLX Comparison
COO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COO stands at 16.89B. In comparison, HOLX has a market cap of 13.11B. Regarding current trading prices, COO is priced at $84.44, while HOLX trades at $58.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COO currently has a P/E ratio of 40.79, whereas HOLX's P/E ratio is 24.71. In terms of profitability, COO's ROE is +0.05%, compared to HOLX's ROE of +0.11%. Regarding short-term risk, COO is less volatile compared to HOLX. This indicates potentially lower risk in terms of short-term price fluctuations for COO.
COO vs ATR Comparison
COO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COO stands at 16.89B. In comparison, ATR has a market cap of 10.27B. Regarding current trading prices, COO is priced at $84.44, while ATR trades at $155.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COO currently has a P/E ratio of 40.79, whereas ATR's P/E ratio is 28.43. In terms of profitability, COO's ROE is +0.05%, compared to ATR's ROE of +0.15%. Regarding short-term risk, COO is less volatile compared to ATR. This indicates potentially lower risk in terms of short-term price fluctuations for COO.
COO vs MASI Comparison
COO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COO stands at 16.89B. In comparison, MASI has a market cap of 8.87B. Regarding current trading prices, COO is priced at $84.44, while MASI trades at $163.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COO currently has a P/E ratio of 40.79, whereas MASI's P/E ratio is -29.96. In terms of profitability, COO's ROE is +0.05%, compared to MASI's ROE of -0.23%. Regarding short-term risk, COO is less volatile compared to MASI. This indicates potentially lower risk in terms of short-term price fluctuations for COO.
COO vs RGEN Comparison
COO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COO stands at 16.89B. In comparison, RGEN has a market cap of 7.51B. Regarding current trading prices, COO is priced at $84.44, while RGEN trades at $133.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COO currently has a P/E ratio of 40.79, whereas RGEN's P/E ratio is -318.38. In terms of profitability, COO's ROE is +0.05%, compared to RGEN's ROE of -0.01%. Regarding short-term risk, COO is less volatile compared to RGEN. This indicates potentially lower risk in terms of short-term price fluctuations for COO.
COO vs STVN Comparison
COO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COO stands at 16.89B. In comparison, STVN has a market cap of 6.44B. Regarding current trading prices, COO is priced at $84.44, while STVN trades at $23.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COO currently has a P/E ratio of 40.79, whereas STVN's P/E ratio is 48.16. In terms of profitability, COO's ROE is +0.05%, compared to STVN's ROE of +0.09%. Regarding short-term risk, COO is less volatile compared to STVN. This indicates potentially lower risk in terms of short-term price fluctuations for COO.
COO vs MMSI Comparison
COO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COO stands at 16.89B. In comparison, MMSI has a market cap of 5.83B. Regarding current trading prices, COO is priced at $84.44, while MMSI trades at $98.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COO currently has a P/E ratio of 40.79, whereas MMSI's P/E ratio is 48.40. In terms of profitability, COO's ROE is +0.05%, compared to MMSI's ROE of +0.09%. Regarding short-term risk, COO is less volatile compared to MMSI. This indicates potentially lower risk in terms of short-term price fluctuations for COO.
COO vs TFX Comparison
COO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COO stands at 16.89B. In comparison, TFX has a market cap of 5.71B. Regarding current trading prices, COO is priced at $84.44, while TFX trades at $129.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COO currently has a P/E ratio of 40.79, whereas TFX's P/E ratio is 39.90. In terms of profitability, COO's ROE is +0.05%, compared to TFX's ROE of +0.03%. Regarding short-term risk, COO is less volatile compared to TFX. This indicates potentially lower risk in terms of short-term price fluctuations for COO.
COO vs BLCO Comparison
COO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COO stands at 16.89B. In comparison, BLCO has a market cap of 4.21B. Regarding current trading prices, COO is priced at $84.44, while BLCO trades at $11.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COO currently has a P/E ratio of 40.79, whereas BLCO's P/E ratio is -11.68. In terms of profitability, COO's ROE is +0.05%, compared to BLCO's ROE of -0.08%. Regarding short-term risk, COO is less volatile compared to BLCO. This indicates potentially lower risk in terms of short-term price fluctuations for COO.
COO vs ICUI Comparison
COO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COO stands at 16.89B. In comparison, ICUI has a market cap of 3.55B. Regarding current trading prices, COO is priced at $84.44, while ICUI trades at $144.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COO currently has a P/E ratio of 40.79, whereas ICUI's P/E ratio is -29.88. In terms of profitability, COO's ROE is +0.05%, compared to ICUI's ROE of -0.06%. Regarding short-term risk, COO is less volatile compared to ICUI. This indicates potentially lower risk in terms of short-term price fluctuations for COO.
COO vs HAE Comparison
COO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COO stands at 16.89B. In comparison, HAE has a market cap of 3.53B. Regarding current trading prices, COO is priced at $84.44, while HAE trades at $70.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COO currently has a P/E ratio of 40.79, whereas HAE's P/E ratio is 27.68. In terms of profitability, COO's ROE is +0.05%, compared to HAE's ROE of +0.14%. Regarding short-term risk, COO is less volatile compared to HAE. This indicates potentially lower risk in terms of short-term price fluctuations for COO.
COO vs XRAY Comparison
COO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COO stands at 16.89B. In comparison, XRAY has a market cap of 3.34B. Regarding current trading prices, COO is priced at $84.44, while XRAY trades at $16.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COO currently has a P/E ratio of 40.79, whereas XRAY's P/E ratio is -3.74. In terms of profitability, COO's ROE is +0.05%, compared to XRAY's ROE of -0.34%. Regarding short-term risk, COO is less volatile compared to XRAY. This indicates potentially lower risk in terms of short-term price fluctuations for COO.
COO vs QDEL Comparison
COO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COO stands at 16.89B. In comparison, QDEL has a market cap of 2.53B. Regarding current trading prices, COO is priced at $84.44, while QDEL trades at $37.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COO currently has a P/E ratio of 40.79, whereas QDEL's P/E ratio is -1.23. In terms of profitability, COO's ROE is +0.05%, compared to QDEL's ROE of -0.64%. Regarding short-term risk, COO is less volatile compared to QDEL. This indicates potentially lower risk in terms of short-term price fluctuations for COO.
COO vs WRBY Comparison
COO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COO stands at 16.89B. In comparison, WRBY has a market cap of 2.29B. Regarding current trading prices, COO is priced at $84.44, while WRBY trades at $18.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COO currently has a P/E ratio of 40.79, whereas WRBY's P/E ratio is -111.15. In terms of profitability, COO's ROE is +0.05%, compared to WRBY's ROE of -0.06%. Regarding short-term risk, COO is less volatile compared to WRBY. This indicates potentially lower risk in terms of short-term price fluctuations for COO.
COO vs NVCR Comparison
COO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COO stands at 16.89B. In comparison, NVCR has a market cap of 2.07B. Regarding current trading prices, COO is priced at $84.44, while NVCR trades at $18.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COO currently has a P/E ratio of 40.79, whereas NVCR's P/E ratio is -12.30. In terms of profitability, COO's ROE is +0.05%, compared to NVCR's ROE of -0.45%. Regarding short-term risk, COO is less volatile compared to NVCR. This indicates potentially lower risk in terms of short-term price fluctuations for COO.
COO vs LMAT Comparison
COO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COO stands at 16.89B. In comparison, LMAT has a market cap of 1.86B. Regarding current trading prices, COO is priced at $84.44, while LMAT trades at $82.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COO currently has a P/E ratio of 40.79, whereas LMAT's P/E ratio is 41.86. In terms of profitability, COO's ROE is +0.05%, compared to LMAT's ROE of +0.14%. Regarding short-term risk, COO is less volatile compared to LMAT. This indicates potentially lower risk in terms of short-term price fluctuations for COO.
COO vs ATRC Comparison
COO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COO stands at 16.89B. In comparison, ATRC has a market cap of 1.57B. Regarding current trading prices, COO is priced at $84.44, while ATRC trades at $31.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COO currently has a P/E ratio of 40.79, whereas ATRC's P/E ratio is -39.27. In terms of profitability, COO's ROE is +0.05%, compared to ATRC's ROE of -0.08%. Regarding short-term risk, COO is less volatile compared to ATRC. This indicates potentially lower risk in terms of short-term price fluctuations for COO.
COO vs AZTA Comparison
COO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COO stands at 16.89B. In comparison, AZTA has a market cap of 1.29B. Regarding current trading prices, COO is priced at $84.44, while AZTA trades at $28.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COO currently has a P/E ratio of 40.79, whereas AZTA's P/E ratio is -8.93. In terms of profitability, COO's ROE is +0.05%, compared to AZTA's ROE of -0.08%. Regarding short-term risk, COO is less volatile compared to AZTA. This indicates potentially lower risk in terms of short-term price fluctuations for COO.
COO vs KMTS Comparison
COO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COO stands at 16.89B. In comparison, KMTS has a market cap of 1.21B. Regarding current trading prices, COO is priced at $84.44, while KMTS trades at $23.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COO currently has a P/E ratio of 40.79, whereas KMTS's P/E ratio is -12.28. In terms of profitability, COO's ROE is +0.05%, compared to KMTS's ROE of N/A. Regarding short-term risk, COO is less volatile compared to KMTS. This indicates potentially lower risk in terms of short-term price fluctuations for COO.
COO vs BLFS Comparison
COO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COO stands at 16.89B. In comparison, BLFS has a market cap of 1.14B. Regarding current trading prices, COO is priced at $84.44, while BLFS trades at $23.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COO currently has a P/E ratio of 40.79, whereas BLFS's P/E ratio is -95.56. In terms of profitability, COO's ROE is +0.05%, compared to BLFS's ROE of -0.06%. Regarding short-term risk, COO is less volatile compared to BLFS. This indicates potentially lower risk in terms of short-term price fluctuations for COO.
COO vs PLSE Comparison
COO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COO stands at 16.89B. In comparison, PLSE has a market cap of 1.13B. Regarding current trading prices, COO is priced at $84.44, while PLSE trades at $16.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COO currently has a P/E ratio of 40.79, whereas PLSE's P/E ratio is -18.25. In terms of profitability, COO's ROE is +0.05%, compared to PLSE's ROE of -0.83%. Regarding short-term risk, COO is less volatile compared to PLSE. This indicates potentially lower risk in terms of short-term price fluctuations for COO.
COO vs STAA Comparison
COO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COO stands at 16.89B. In comparison, STAA has a market cap of 1.00B. Regarding current trading prices, COO is priced at $84.44, while STAA trades at $20.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COO currently has a P/E ratio of 40.79, whereas STAA's P/E ratio is -49.44. In terms of profitability, COO's ROE is +0.05%, compared to STAA's ROE of -0.05%. Regarding short-term risk, COO is less volatile compared to STAA. This indicates potentially lower risk in terms of short-term price fluctuations for COO.
COO vs ATRI Comparison
COO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COO stands at 16.89B. In comparison, ATRI has a market cap of 809.44M. Regarding current trading prices, COO is priced at $84.44, while ATRI trades at $459.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COO currently has a P/E ratio of 40.79, whereas ATRI's P/E ratio is 64.50. In terms of profitability, COO's ROE is +0.05%, compared to ATRI's ROE of +0.05%. Regarding short-term risk, COO is more volatile compared to ATRI. This indicates potentially higher risk in terms of short-term price fluctuations for COO.
COO vs ANGO Comparison
COO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COO stands at 16.89B. In comparison, ANGO has a market cap of 388.61M. Regarding current trading prices, COO is priced at $84.44, while ANGO trades at $9.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COO currently has a P/E ratio of 40.79, whereas ANGO's P/E ratio is -9.48. In terms of profitability, COO's ROE is +0.05%, compared to ANGO's ROE of -0.21%. Regarding short-term risk, COO is less volatile compared to ANGO. This indicates potentially lower risk in terms of short-term price fluctuations for COO.
COO vs SMTI Comparison
COO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COO stands at 16.89B. In comparison, SMTI has a market cap of 305.48M. Regarding current trading prices, COO is priced at $84.44, while SMTI trades at $34.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COO currently has a P/E ratio of 40.79, whereas SMTI's P/E ratio is -30.15. In terms of profitability, COO's ROE is +0.05%, compared to SMTI's ROE of -0.24%. Regarding short-term risk, COO is less volatile compared to SMTI. This indicates potentially lower risk in terms of short-term price fluctuations for COO.
COO vs NNNN Comparison
COO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COO stands at 16.89B. In comparison, NNNN has a market cap of 299.78M. Regarding current trading prices, COO is priced at $84.44, while NNNN trades at $6.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COO currently has a P/E ratio of 40.79, whereas NNNN's P/E ratio is 136.60. In terms of profitability, COO's ROE is +0.05%, compared to NNNN's ROE of N/A. Regarding short-term risk, COO is less volatile compared to NNNN. This indicates potentially lower risk in terms of short-term price fluctuations for COO.
COO vs NYXH Comparison
COO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COO stands at 16.89B. In comparison, NYXH has a market cap of 205.63M. Regarding current trading prices, COO is priced at $84.44, while NYXH trades at $5.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COO currently has a P/E ratio of 40.79, whereas NYXH's P/E ratio is -2.92. In terms of profitability, COO's ROE is +0.05%, compared to NYXH's ROE of -0.56%. Regarding short-term risk, COO is less volatile compared to NYXH. This indicates potentially lower risk in terms of short-term price fluctuations for COO.
COO vs OSUR Comparison
COO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COO stands at 16.89B. In comparison, OSUR has a market cap of 199.72M. Regarding current trading prices, COO is priced at $84.44, while OSUR trades at $2.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COO currently has a P/E ratio of 40.79, whereas OSUR's P/E ratio is -10.27. In terms of profitability, COO's ROE is +0.05%, compared to OSUR's ROE of -0.05%. Regarding short-term risk, COO is less volatile compared to OSUR. This indicates potentially lower risk in terms of short-term price fluctuations for COO.
COO vs STXS Comparison
COO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COO stands at 16.89B. In comparison, STXS has a market cap of 179.70M. Regarding current trading prices, COO is priced at $84.44, while STXS trades at $2.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COO currently has a P/E ratio of 40.79, whereas STXS's P/E ratio is -6.97. In terms of profitability, COO's ROE is +0.05%, compared to STXS's ROE of -1.49%. Regarding short-term risk, COO is less volatile compared to STXS. This indicates potentially lower risk in terms of short-term price fluctuations for COO.
COO vs UTMD Comparison
COO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COO stands at 16.89B. In comparison, UTMD has a market cap of 177.28M. Regarding current trading prices, COO is priced at $84.44, while UTMD trades at $54.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COO currently has a P/E ratio of 40.79, whereas UTMD's P/E ratio is 14.25. In terms of profitability, COO's ROE is +0.05%, compared to UTMD's ROE of +0.11%. Regarding short-term risk, COO is less volatile compared to UTMD. This indicates potentially lower risk in terms of short-term price fluctuations for COO.
COO vs ZTEK Comparison
COO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COO stands at 16.89B. In comparison, ZTEK has a market cap of 163.77M. Regarding current trading prices, COO is priced at $84.44, while ZTEK trades at $1.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COO currently has a P/E ratio of 40.79, whereas ZTEK's P/E ratio is -19.62. In terms of profitability, COO's ROE is +0.05%, compared to ZTEK's ROE of -0.58%. Regarding short-term risk, COO is less volatile compared to ZTEK. This indicates potentially lower risk in terms of short-term price fluctuations for COO.
COO vs KRMD Comparison
COO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COO stands at 16.89B. In comparison, KRMD has a market cap of 149.96M. Regarding current trading prices, COO is priced at $84.44, while KRMD trades at $3.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COO currently has a P/E ratio of 40.79, whereas KRMD's P/E ratio is -25.00. In terms of profitability, COO's ROE is +0.05%, compared to KRMD's ROE of -0.34%. Regarding short-term risk, COO is less volatile compared to KRMD. This indicates potentially lower risk in terms of short-term price fluctuations for COO.
COO vs ZJYL Comparison
COO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COO stands at 16.89B. In comparison, ZJYL has a market cap of 140.63M. Regarding current trading prices, COO is priced at $84.44, while ZJYL trades at $0.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COO currently has a P/E ratio of 40.79, whereas ZJYL's P/E ratio is 44.92. In terms of profitability, COO's ROE is +0.05%, compared to ZJYL's ROE of +0.13%. Regarding short-term risk, COO is less volatile compared to ZJYL. This indicates potentially lower risk in terms of short-term price fluctuations for COO.
COO vs PDEX Comparison
COO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COO stands at 16.89B. In comparison, PDEX has a market cap of 131.32M. Regarding current trading prices, COO is priced at $84.44, while PDEX trades at $40.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COO currently has a P/E ratio of 40.79, whereas PDEX's P/E ratio is 14.59. In terms of profitability, COO's ROE is +0.05%, compared to PDEX's ROE of +0.29%. Regarding short-term risk, COO is less volatile compared to PDEX. This indicates potentially lower risk in terms of short-term price fluctuations for COO.
COO vs INFU Comparison
COO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COO stands at 16.89B. In comparison, INFU has a market cap of 114.53M. Regarding current trading prices, COO is priced at $84.44, while INFU trades at $5.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COO currently has a P/E ratio of 40.79, whereas INFU's P/E ratio is 49.64. In terms of profitability, COO's ROE is +0.05%, compared to INFU's ROE of +0.04%. Regarding short-term risk, COO is less volatile compared to INFU. This indicates potentially lower risk in terms of short-term price fluctuations for COO.
COO vs MBOT Comparison
COO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COO stands at 16.89B. In comparison, MBOT has a market cap of 88.60M. Regarding current trading prices, COO is priced at $84.44, while MBOT trades at $2.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COO currently has a P/E ratio of 40.79, whereas MBOT's P/E ratio is -3.49. In terms of profitability, COO's ROE is +0.05%, compared to MBOT's ROE of -2.34%. Regarding short-term risk, COO is less volatile compared to MBOT. This indicates potentially lower risk in terms of short-term price fluctuations for COO.
COO vs MLSS Comparison
COO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COO stands at 16.89B. In comparison, MLSS has a market cap of 72.52M. Regarding current trading prices, COO is priced at $84.44, while MLSS trades at $0.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COO currently has a P/E ratio of 40.79, whereas MLSS's P/E ratio is -15.42. In terms of profitability, COO's ROE is +0.05%, compared to MLSS's ROE of -0.66%. Regarding short-term risk, COO is less volatile compared to MLSS. This indicates potentially lower risk in terms of short-term price fluctuations for COO.
COO vs AKYA Comparison
COO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COO stands at 16.89B. In comparison, AKYA has a market cap of 57.86M. Regarding current trading prices, COO is priced at $84.44, while AKYA trades at $1.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COO currently has a P/E ratio of 40.79, whereas AKYA's P/E ratio is -1.04. In terms of profitability, COO's ROE is +0.05%, compared to AKYA's ROE of -2.91%. Regarding short-term risk, COO is less volatile compared to AKYA. This indicates potentially lower risk in terms of short-term price fluctuations for COO.
COO vs OMIC Comparison
COO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COO stands at 16.89B. In comparison, OMIC has a market cap of 50.77M. Regarding current trading prices, COO is priced at $84.44, while OMIC trades at $20.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COO currently has a P/E ratio of 40.79, whereas OMIC's P/E ratio is -0.58. In terms of profitability, COO's ROE is +0.05%, compared to OMIC's ROE of -0.58%. Regarding short-term risk, COO is more volatile compared to OMIC. This indicates potentially higher risk in terms of short-term price fluctuations for COO.
COO vs IGAP Comparison
COO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COO stands at 16.89B. In comparison, IGAP has a market cap of 50.23M. Regarding current trading prices, COO is priced at $84.44, while IGAP trades at $3.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COO currently has a P/E ratio of 40.79, whereas IGAP's P/E ratio is -10.52. In terms of profitability, COO's ROE is +0.05%, compared to IGAP's ROE of +4.55%. Regarding short-term risk, COO is less volatile compared to IGAP. This indicates potentially lower risk in terms of short-term price fluctuations for COO.
COO vs POCI Comparison
COO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COO stands at 16.89B. In comparison, POCI has a market cap of 36.36M. Regarding current trading prices, COO is priced at $84.44, while POCI trades at $4.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COO currently has a P/E ratio of 40.79, whereas POCI's P/E ratio is -7.30. In terms of profitability, COO's ROE is +0.05%, compared to POCI's ROE of -0.39%. Regarding short-term risk, COO is less volatile compared to POCI. This indicates potentially lower risk in terms of short-term price fluctuations for COO.
COO vs DXR Comparison
COO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COO stands at 16.89B. In comparison, DXR has a market cap of 35.07M. Regarding current trading prices, COO is priced at $84.44, while DXR trades at $7.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COO currently has a P/E ratio of 40.79, whereas DXR's P/E ratio is -80.56. In terms of profitability, COO's ROE is +0.05%, compared to DXR's ROE of +0.02%. Regarding short-term risk, COO is less volatile compared to DXR. This indicates potentially lower risk in terms of short-term price fluctuations for COO.
COO vs FEMY Comparison
COO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COO stands at 16.89B. In comparison, FEMY has a market cap of 29.42M. Regarding current trading prices, COO is priced at $84.44, while FEMY trades at $1.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COO currently has a P/E ratio of 40.79, whereas FEMY's P/E ratio is -1.27. In terms of profitability, COO's ROE is +0.05%, compared to FEMY's ROE of -2.14%. Regarding short-term risk, COO is less volatile compared to FEMY. This indicates potentially lower risk in terms of short-term price fluctuations for COO.
COO vs SDC Comparison
COO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COO stands at 16.89B. In comparison, SDC has a market cap of 29.11M. Regarding current trading prices, COO is priced at $84.44, while SDC trades at $0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COO currently has a P/E ratio of 40.79, whereas SDC's P/E ratio is -0.03. In terms of profitability, COO's ROE is +0.05%, compared to SDC's ROE of -1.96%. Regarding short-term risk, COO is less volatile compared to SDC. This indicates potentially lower risk in terms of short-term price fluctuations for COO.
COO vs IVC Comparison
COO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COO stands at 16.89B. In comparison, IVC has a market cap of 24.91M. Regarding current trading prices, COO is priced at $84.44, while IVC trades at $0.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COO currently has a P/E ratio of 40.79, whereas IVC's P/E ratio is -0.79. In terms of profitability, COO's ROE is +0.05%, compared to IVC's ROE of -0.46%. Regarding short-term risk, COO is less volatile compared to IVC. This indicates potentially lower risk in terms of short-term price fluctuations for COO.
COO vs NXGLW Comparison
COO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COO stands at 16.89B. In comparison, NXGLW has a market cap of 24.53M. Regarding current trading prices, COO is priced at $84.44, while NXGLW trades at $0.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COO currently has a P/E ratio of 40.79, whereas NXGLW's P/E ratio is -0.27. In terms of profitability, COO's ROE is +0.05%, compared to NXGLW's ROE of -0.68%. Regarding short-term risk, COO is less volatile compared to NXGLW. This indicates potentially lower risk in terms of short-term price fluctuations for COO.
COO vs RVP Comparison
COO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COO stands at 16.89B. In comparison, RVP has a market cap of 22.67M. Regarding current trading prices, COO is priced at $84.44, while RVP trades at $0.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COO currently has a P/E ratio of 40.79, whereas RVP's P/E ratio is -1.89. In terms of profitability, COO's ROE is +0.05%, compared to RVP's ROE of -0.13%. Regarding short-term risk, COO is less volatile compared to RVP. This indicates potentially lower risk in terms of short-term price fluctuations for COO.
COO vs NEPH Comparison
COO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COO stands at 16.89B. In comparison, NEPH has a market cap of 21.95M. Regarding current trading prices, COO is priced at $84.44, while NEPH trades at $2.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COO currently has a P/E ratio of 40.79, whereas NEPH's P/E ratio is 207.10. In terms of profitability, COO's ROE is +0.05%, compared to NEPH's ROE of +0.01%. Regarding short-term risk, COO is less volatile compared to NEPH. This indicates potentially lower risk in terms of short-term price fluctuations for COO.
COO vs NXGL Comparison
COO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COO stands at 16.89B. In comparison, NXGL has a market cap of 21.28M. Regarding current trading prices, COO is priced at $84.44, while NXGL trades at $2.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COO currently has a P/E ratio of 40.79, whereas NXGL's P/E ratio is -5.56. In terms of profitability, COO's ROE is +0.05%, compared to NXGL's ROE of -0.68%. Regarding short-term risk, COO is less volatile compared to NXGL. This indicates potentially lower risk in terms of short-term price fluctuations for COO.
COO vs HBIO Comparison
COO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COO stands at 16.89B. In comparison, HBIO has a market cap of 15.57M. Regarding current trading prices, COO is priced at $84.44, while HBIO trades at $0.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COO currently has a P/E ratio of 40.79, whereas HBIO's P/E ratio is -1.26. In terms of profitability, COO's ROE is +0.05%, compared to HBIO's ROE of -0.19%. Regarding short-term risk, COO is less volatile compared to HBIO. This indicates potentially lower risk in terms of short-term price fluctuations for COO.
COO vs LUCYW Comparison
COO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COO stands at 16.89B. In comparison, LUCYW has a market cap of 13.82M. Regarding current trading prices, COO is priced at $84.44, while LUCYW trades at $0.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COO currently has a P/E ratio of 40.79, whereas LUCYW's P/E ratio is N/A. In terms of profitability, COO's ROE is +0.05%, compared to LUCYW's ROE of -0.99%. Regarding short-term risk, COO is less volatile compared to LUCYW. This indicates potentially lower risk in terms of short-term price fluctuations for COO.
COO vs MHUA Comparison
COO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COO stands at 16.89B. In comparison, MHUA has a market cap of 13.30M. Regarding current trading prices, COO is priced at $84.44, while MHUA trades at $0.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COO currently has a P/E ratio of 40.79, whereas MHUA's P/E ratio is 1.05. In terms of profitability, COO's ROE is +0.05%, compared to MHUA's ROE of +0.09%. Regarding short-term risk, COO is less volatile compared to MHUA. This indicates potentially lower risk in terms of short-term price fluctuations for COO.
COO vs EKSO Comparison
COO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COO stands at 16.89B. In comparison, EKSO has a market cap of 12.49M. Regarding current trading prices, COO is priced at $84.44, while EKSO trades at $0.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COO currently has a P/E ratio of 40.79, whereas EKSO's P/E ratio is -0.77. In terms of profitability, COO's ROE is +0.05%, compared to EKSO's ROE of -0.82%. Regarding short-term risk, COO is less volatile compared to EKSO. This indicates potentially lower risk in terms of short-term price fluctuations for COO.
COO vs POAI Comparison
COO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COO stands at 16.89B. In comparison, POAI has a market cap of 10.00M. Regarding current trading prices, COO is priced at $84.44, while POAI trades at $1.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COO currently has a P/E ratio of 40.79, whereas POAI's P/E ratio is -0.56. In terms of profitability, COO's ROE is +0.05%, compared to POAI's ROE of -5.11%. Regarding short-term risk, COO is less volatile compared to POAI. This indicates potentially lower risk in terms of short-term price fluctuations for COO.
COO vs WOK Comparison
COO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COO stands at 16.89B. In comparison, WOK has a market cap of 7.30M. Regarding current trading prices, COO is priced at $84.44, while WOK trades at $0.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COO currently has a P/E ratio of 40.79, whereas WOK's P/E ratio is -1.85. In terms of profitability, COO's ROE is +0.05%, compared to WOK's ROE of N/A. Regarding short-term risk, COO is less volatile compared to WOK. This indicates potentially lower risk in terms of short-term price fluctuations for COO.
COO vs NSTG Comparison
COO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COO stands at 16.89B. In comparison, NSTG has a market cap of 5.07M. Regarding current trading prices, COO is priced at $84.44, while NSTG trades at $0.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COO currently has a P/E ratio of 40.79, whereas NSTG's P/E ratio is -0.03. In terms of profitability, COO's ROE is +0.05%, compared to NSTG's ROE of -1.43%. Regarding short-term risk, COO is less volatile compared to NSTG. This indicates potentially lower risk in terms of short-term price fluctuations for COO.
COO vs STSS Comparison
COO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COO stands at 16.89B. In comparison, STSS has a market cap of 4.75M. Regarding current trading prices, COO is priced at $84.44, while STSS trades at $4.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COO currently has a P/E ratio of 40.79, whereas STSS's P/E ratio is N/A. In terms of profitability, COO's ROE is +0.05%, compared to STSS's ROE of -1.65%. Regarding short-term risk, COO is less volatile compared to STSS. This indicates potentially lower risk in terms of short-term price fluctuations for COO.
COO vs LUCY Comparison
COO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COO stands at 16.89B. In comparison, LUCY has a market cap of 4.59M. Regarding current trading prices, COO is priced at $84.44, while LUCY trades at $1.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COO currently has a P/E ratio of 40.79, whereas LUCY's P/E ratio is -0.36. In terms of profitability, COO's ROE is +0.05%, compared to LUCY's ROE of -0.99%. Regarding short-term risk, COO is less volatile compared to LUCY. This indicates potentially lower risk in terms of short-term price fluctuations for COO.
COO vs GCTK Comparison
COO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COO stands at 16.89B. In comparison, GCTK has a market cap of 3.80M. Regarding current trading prices, COO is priced at $84.44, while GCTK trades at $0.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COO currently has a P/E ratio of 40.79, whereas GCTK's P/E ratio is N/A. In terms of profitability, COO's ROE is +0.05%, compared to GCTK's ROE of +4.55%. Regarding short-term risk, COO is less volatile compared to GCTK. This indicates potentially lower risk in terms of short-term price fluctuations for COO.
COO vs GMVD Comparison
COO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COO stands at 16.89B. In comparison, GMVD has a market cap of 1.80M. Regarding current trading prices, COO is priced at $84.44, while GMVD trades at $0.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COO currently has a P/E ratio of 40.79, whereas GMVD's P/E ratio is -0.01. In terms of profitability, COO's ROE is +0.05%, compared to GMVD's ROE of +2.09%. Regarding short-term risk, COO is less volatile compared to GMVD. This indicates potentially lower risk in terms of short-term price fluctuations for COO.
COO vs GMVDW Comparison
COO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COO stands at 16.89B. In comparison, GMVDW has a market cap of 1.80M. Regarding current trading prices, COO is priced at $84.44, while GMVDW trades at $7.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COO currently has a P/E ratio of 40.79, whereas GMVDW's P/E ratio is N/A. In terms of profitability, COO's ROE is +0.05%, compared to GMVDW's ROE of +2.09%. Regarding short-term risk, COO is less volatile compared to GMVDW. This indicates potentially lower risk in terms of short-term price fluctuations for COO.
COO vs AVGR Comparison
COO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COO stands at 16.89B. In comparison, AVGR has a market cap of 1.52M. Regarding current trading prices, COO is priced at $84.44, while AVGR trades at $0.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COO currently has a P/E ratio of 40.79, whereas AVGR's P/E ratio is -0.05. In terms of profitability, COO's ROE is +0.05%, compared to AVGR's ROE of -54.25%. Regarding short-term risk, COO is less volatile compared to AVGR. This indicates potentially lower risk in terms of short-term price fluctuations for COO.